SG11202005290QA - Bifunctional proteins combining checkpoint blockade for targeted therapy - Google Patents
Bifunctional proteins combining checkpoint blockade for targeted therapyInfo
- Publication number
- SG11202005290QA SG11202005290QA SG11202005290QA SG11202005290QA SG11202005290QA SG 11202005290Q A SG11202005290Q A SG 11202005290QA SG 11202005290Q A SG11202005290Q A SG 11202005290QA SG 11202005290Q A SG11202005290Q A SG 11202005290QA SG 11202005290Q A SG11202005290Q A SG 11202005290QA
- Authority
- SG
- Singapore
- Prior art keywords
- targeted therapy
- checkpoint blockade
- bifunctional proteins
- proteins combining
- combining checkpoint
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title 1
- 230000005746 immune checkpoint blockade Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000002626 targeted therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636825P | 2018-02-28 | 2018-02-28 | |
| PCT/US2019/019786 WO2019168947A1 (en) | 2018-02-28 | 2019-02-27 | Bifunctional proteins combining checkpoint blockade for targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005290QA true SG11202005290QA (en) | 2020-07-29 |
Family
ID=67806427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005290QA SG11202005290QA (en) | 2018-02-28 | 2019-02-27 | Bifunctional proteins combining checkpoint blockade for targeted therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11780922B2 (en) |
| EP (1) | EP3758735B1 (en) |
| JP (1) | JP7464525B2 (en) |
| KR (1) | KR102469248B1 (en) |
| CN (1) | CN111565738B (en) |
| AU (1) | AU2019227715B2 (en) |
| BR (1) | BR112020013854A2 (en) |
| CA (1) | CA3085467A1 (en) |
| ES (1) | ES2974252T3 (en) |
| RU (1) | RU2756899C1 (en) |
| SG (1) | SG11202005290QA (en) |
| TW (1) | TWI731310B (en) |
| WO (1) | WO2019168947A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710645A2 (en) | 2006-04-07 | 2012-03-20 | The Procter & Gamble Company | ANTIBODIES BINDING TO HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES OF THE SAME |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| CA3082036A1 (en) * | 2017-12-29 | 2019-07-04 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| CN113164597A (en) | 2018-09-24 | 2021-07-23 | 爱尔皮奥制药公司 | Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF |
| WO2020114355A1 (en) * | 2018-12-03 | 2020-06-11 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd | Recombinant protein targeting pd-l1 and vegf |
| EP4093765A4 (en) * | 2020-01-21 | 2023-06-28 | Wuxi Biologics (Shanghai) Co. Ltd. | A bispecific anti-pd-l1/vegf antibody and uses thereof |
| CN113754776A (en) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | anti-PD-L1/VEGF fusion protein |
| TW202413427A (en) * | 2022-08-09 | 2024-04-01 | 大陸商上海濟煜醫藥科技有限公司 | An antibody targeting pd-1 and vegf and use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ576445A (en) * | 2006-11-02 | 2012-03-30 | Daniel J Capon | Hybrid immunoglobulins with moving parts |
| KR101397088B1 (en) * | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | A fusion protein for inhibiting both angiogenesis and tumor cell proliferation, and composition comprising the same |
| CA2872030A1 (en) * | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| JP6312659B2 (en) * | 2012-05-31 | 2018-04-18 | ジェネンテック， インコーポレイテッド | Cancer treatment method using PD-1 binding antagonist and VEGF antagonist |
| CA2878843A1 (en) * | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
| KR102049990B1 (en) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | Fusion protein comprising anti-c-Met antibody and VEGF binding fragment |
| WO2014197369A1 (en) * | 2013-06-06 | 2014-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| CN104341504B (en) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | Bispecific antibody |
| JP2016540042A (en) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ， インコーポレイテッド | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| US9527901B2 (en) | 2014-03-24 | 2016-12-27 | Macroimmune Inc | Recombinant bi-functional fusion proteins, preparations and methods for treating disease |
| CN106659772B (en) | 2014-06-26 | 2021-08-31 | 耶鲁大学 | Compositions and methods for modulating renalase in the treatment of diseases and disorders |
| EP3227436A4 (en) * | 2014-12-05 | 2018-06-20 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| TWI595006B (en) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
| AU2016229053B2 (en) * | 2015-03-11 | 2018-07-12 | Ap Biosciences, Inc. | Fusion protein comprising a ligand binding domain of VEGF and PDGF |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| EP3377112A4 (en) | 2015-11-18 | 2019-06-12 | Sorrento Therapeutics, Inc. | Chemically-locked bispecific antibodies |
| CN109310755A (en) * | 2016-02-02 | 2019-02-05 | 卡德门企业有限公司 | The bispecific binding protein of PD-L1 and KDR |
| KR20180121786A (en) * | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | Antibodies, pharmaceutical compositions and methods |
| MX2018012493A (en) * | 2016-04-15 | 2019-06-06 | Genentech Inc | Methods for monitoring and treating cancer. |
| WO2017200173A1 (en) * | 2016-05-19 | 2017-11-23 | 삼성전자 주식회사 | Vegf-binding fragment mutant, and fusion protein comprising vegf-binding fragment mutant and anti-c-met antibody |
| UA126905C2 (en) | 2016-06-13 | 2023-02-22 | Ай-Маб Байофарма Юес Лімітед | Anti-pd-l1 antibodies and uses thereof |
| CN107602702A (en) * | 2017-09-22 | 2018-01-19 | 生标（上海）医疗器械科技有限公司 | Antibody that is a kind of while targetting people p185 and VEGF and its application |
| CN109575140B (en) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | Dual-targeting fusion proteins targeting PD-1 or PD-L1 and targeting the VEGF family and uses thereof |
| CA3082036A1 (en) * | 2017-12-29 | 2019-07-04 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
-
2019
- 2019-02-27 SG SG11202005290QA patent/SG11202005290QA/en unknown
- 2019-02-27 CN CN201980007127.7A patent/CN111565738B/en active Active
- 2019-02-27 TW TW108106894A patent/TWI731310B/en active
- 2019-02-27 WO PCT/US2019/019786 patent/WO2019168947A1/en unknown
- 2019-02-27 JP JP2020540311A patent/JP7464525B2/en active Active
- 2019-02-27 CA CA3085467A patent/CA3085467A1/en active Pending
- 2019-02-27 KR KR1020207018170A patent/KR102469248B1/en active IP Right Grant
- 2019-02-27 ES ES19759945T patent/ES2974252T3/en active Active
- 2019-02-27 AU AU2019227715A patent/AU2019227715B2/en active Active
- 2019-02-27 BR BR112020013854-1A patent/BR112020013854A2/en not_active Application Discontinuation
- 2019-02-27 RU RU2020125987A patent/RU2756899C1/en active
- 2019-02-27 EP EP19759945.9A patent/EP3758735B1/en active Active
-
2020
- 2020-06-09 US US16/896,597 patent/US11780922B2/en active Active
-
2023
- 2023-06-26 US US18/214,160 patent/US20230322931A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7464525B2 (en) | 2024-04-09 |
| US20200299389A1 (en) | 2020-09-24 |
| TWI731310B (en) | 2021-06-21 |
| AU2019227715A1 (en) | 2020-06-18 |
| RU2756899C1 (en) | 2021-10-06 |
| NZ765074A (en) | 2023-11-24 |
| CN111565738A (en) | 2020-08-21 |
| KR102469248B1 (en) | 2022-11-22 |
| WO2019168947A1 (en) | 2019-09-06 |
| CA3085467A1 (en) | 2019-09-06 |
| EP3758735A1 (en) | 2021-01-06 |
| AU2019227715B2 (en) | 2022-03-31 |
| ES2974252T3 (en) | 2024-06-26 |
| WO2019168947A8 (en) | 2019-10-03 |
| EP3758735B1 (en) | 2023-12-13 |
| KR20200088883A (en) | 2020-07-23 |
| BR112020013854A2 (en) | 2020-12-01 |
| EP3758735A4 (en) | 2021-12-08 |
| JP2021511786A (en) | 2021-05-13 |
| TW201945023A (en) | 2019-12-01 |
| CN111565738B (en) | 2023-12-26 |
| US20230322931A1 (en) | 2023-10-12 |
| US11780922B2 (en) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202005290QA (en) | Bifunctional proteins combining checkpoint blockade for targeted therapy | |
| IL253712A0 (en) | Hemiasterlin derivatives for conjugation and therapy | |
| EP3518946A4 (en) | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome | |
| GB201820166D0 (en) | Therapeutic agents | |
| GB201820165D0 (en) | Therapeutic agents | |
| IL282794A (en) | Therapeutic methods | |
| GB201804255D0 (en) | Macrophage-based therapy | |
| IL251349A0 (en) | Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages | |
| IL256000A (en) | Quantifying her 2 protein for optimal cancer therapy | |
| IL290660A (en) | Therapeutic fusion proteins | |
| ZA201904736B (en) | Targeted doxorubicin-gold nanoconjugates for tumor therapy | |
| GB201805816D0 (en) | Therapeutic agents | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| GB201819853D0 (en) | Therapy | |
| ZA201902689B (en) | Therapeutic protein | |
| IL304245A (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
| EP3421039A4 (en) | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor | |
| GB201817385D0 (en) | Therapy | |
| IL268046A (en) | Peptides for therapy | |
| GB201820164D0 (en) | Therapeutic agents | |
| GB201820170D0 (en) | Therapeutic agents | |
| GB201820172D0 (en) | Therapeutic agents | |
| GB201820168D0 (en) | Therapeutic agents | |
| GB201820162D0 (en) | Therapeutic agents | |
| GB201820160D0 (en) | Therapeutic agents |